US company conducts a study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Teres Bio, Inc is starting a new clinical trial of Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis.
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
The clinical trial started in January 18, 2021 and will continue throughout June 30, 2021.
The inclusion parameters are:
- Adolescent or adult subject aged 12 - 65 years.
- Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA.
The exclusion parameters are:
- AD with known hypersensitivity to excipients of TER-101 Ointment
- Participants who are immunocompromised
The contacts and locations are sites of Teres Bio, Encinitas, California; North Miami Beach, Florida; Tampa, Florida; Clarksville, Indiana; Louisville, Kentucky; Saint Joseph, Missouri; High Point, North Carolina; Wilmington, North Carolina; College Station, Texas; Pflugerville, Texas and San Antonio, Texas, United States.
Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood, with changing severity over the years. In children under one year of age, much of the body may be affected. As children get older, the areas on the insides of the knees and elbows are most commonly affected. In adults, the hands and feet are most commonly affected. Scratching the affected areas worsens the symptoms, and those affected have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04753034
